{"id":"golimumab-treatment-optimization","safety":{"commonSideEffects":[{"rate":"10–20%","effect":"Injection site reactions"},{"rate":"10–15%","effect":"Upper respiratory tract infections"},{"rate":"5–10%","effect":"Nasopharyngitis"},{"rate":"<1%","effect":"Tuberculosis reactivation"},{"rate":"2–5%","effect":"Serious infections"},{"rate":"5–10%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Golimumab binds to and neutralizes TNF-α, a key pro-inflammatory cytokine that drives immune-mediated inflammation. By inhibiting TNF-α, it suppresses the inflammatory cascade responsible for tissue damage in autoimmune conditions. This mechanism allows immune tolerance to be restored and inflammatory symptoms to be controlled.","oneSentence":"Golimumab is a monoclonal antibody that blocks tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling in autoimmune and inflammatory diseases.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:33:04.669Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Psoriatic arthritis"},{"name":"Ulcerative colitis"},{"name":"Polyarticular juvenile idiopathic arthritis"}]},"trialDetails":[{"nctId":"NCT04156984","phase":"PHASE4","title":"Comparison of Two Different Golimumab Dosing Regimens for Ulcerative Colitis","status":"COMPLETED","sponsor":"David Drobne","startDate":"2021-04-07","conditions":"Ulcerative Colitis","enrollment":27},{"nctId":"NCT03182166","phase":"PHASE2","title":"Golimumab in Ulcerative Colitis (UC) Patients With Loss of Response (LOR) Followed by Dose Optimization","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2017-11-21","conditions":"Ulcerative Colitis","enrollment":51},{"nctId":"NCT03669029","phase":"PHASE4","title":"Optimization of Golimumab Treatment in Ulcerative Colitis","status":"UNKNOWN","sponsor":"Hospital de Manises","startDate":"2018-10-01","conditions":"Colitis, Ulcerative","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Golimumab treatment optimization.","genericName":"Golimumab treatment optimization.","companyName":"Hospital de Manises","companyId":"hospital-de-manises","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Golimumab is a monoclonal antibody that blocks tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling in autoimmune and inflammatory diseases. Used for Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}